The Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market
The Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market size is forecast to grow from USD 1.4 Billion in 2025 to approximately USD 4.2 Billion by 2035. According to Decision Advisors, a detailed research report on the paroxysmal nocturnal hemoglobinuria therapeutics market indicates that the rapid expansion of the complement inhibitor therapies trend dominates the market, accounting for approximately 60-63% of the total share globally. Alexion Pharmaceuticals (AstraZeneca) leads the market with an estimated 35-40% global market share. The company reported a 2025 revenue of approximately USD 45+ Billion, making it one of the most influential forces shaping industry trends and overall market growth